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Objectives: the first line management of patients with intermittent claudication is `` best medical therapy'' i.e., smoking
cessation, exercise, antiplatelet therapy and risk factors modification. The aim of this study was to assess the current
management of risk factors in primary care and to compare General Practitioner (GP) attitudes and actual management.
Design and Methods: postal questionnaire of all 336 GPs in the referral area (Grampian, Scotland). Questionnaire and
measurement of serum cholesterol, blood glucose and HbA1c of new clinic patients (n 104) with claudication referred by
general practitioners.
Results: a 73% GP response rate was obtained. Ninety-five percent of GPs would treat risk factors. The vast majority
would prescribe aspirin, yet 28% of patients were on no anti-platelet therapy. Eighty-nine percent of GPs would advise an
increase in exercise but only 14% of patients recalled being told to do so. One in seven of the GPs would not check serum
cholesterol, 18% considered cholesterol lowering therapy to be primary prevention and 41% would only treat levels above
5.5 mmol/l. Eighty-five percent of patients were on a statin or had a cholesterol above 5 mmol/L. Seventy-seven percent of
GPs would check glucose levels, and 14% of patients were found to be previously undiagnosed diabetics.
Conclusions: risk factors in claudicants are suboptimally managed. Urgent guidelines for the specific management of
claudicants by general practitioners, as well as strategies to ensure their implementation, are required.
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Intermittent claudication affects between 1.71 and
7.1%2 of the population over 55 years of age. In
terms of the limb, the condition is relatively benign
with less than 10% of claudicants requiring interven-
tion to prevent limb loss and less than 1% per year
requiring amputation.3,4 However, cardiovascular
mortality in patients with intermittent claudication is
twice to three times increased compared to an age and
sex matched population.4 In the Edinburgh Artery
study almost 20% of patients with intermittent
claudication were dead within 5 years,2 13.7% from
cardiovascular causes. The major risk factors for
both cardiovascular disease and peripheral vascular
disease ± cigarette smoking, hypercholesterolemia,
hypertension and diabetes ± are well recognised. The
Joint British recommendations on prevention of cor-
onary heart disease in clinical practice state that
patients with peripheral arterial disease should be
managed in the same way as those with established
coronary heart disease.5Please address all correspondence to: J. Brittenden, Ward 36,
Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 2ZN, UK.
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published a national clinical guideline on `` Drug Ther-
apy for Peripheral Vascular Disease'' in July 1998.6
This guideline recommends that all claudicants
should be prescribed aspirin. Although risk factors
are acknowledged it was felt that specific recommen-
dations for their modification was out with the remit
of the guideline. Currently, no clear guidelines are
available for the management of individual risk fac-
tors in patients with intermittent claudication.
It has been estimated that 55% of claudicants have
hypertension, 14% are diabetic and 56% have abnorm-
alities of lipid metabolism.7 It is unclear what propor-
tion of patients with these risk factors are diagnosed
and treated in primary care prior to attending a spe-
cialist clinic. However, a previous study of patients
with peripheral vascular disease admitted to a regional
vascular unit, revealed that 80% of hypercholester-
olaemic patients were undiagnosed at the time of
hospital admission.8
The aim of this study was to determine the attitudes
of General Practitioners (GPs) to referral, risk factor
management and treatment in patients presenting
with life-style limiting claudication. This involved a
postal survey questionnaire of all GPs within therights reserved.
Table 1. Level of cholesterol at which GPs initiate treatment.
What level of cholesterol would you treat? n %
55 mmol/l 11 5
45 mmol/l 85 36
45.5 mmol/l 42 18
46 mmol/l 54 23
Depends on risk factor profile 43 18
Depends on HDL/cholesterol ratio 6 3
Total 235 100
Fig. 1. GP management at initial patient presentation.
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were asked about the following: antiplatelet therapy,
diabetes, cholesterol, smoking and exercise. The extent
of treatment of these risk factors was also assessed in
new patients attending the vascular out-patient clinic
in order to compare GP atittudes with actual treat-
ment of risk factors.
Materials and Methods
GP questionnaire
A Postal survey questionnaire was sent to all 336 GPs
within the referral area of a regional vascular
unit (Grampian, Scotland) in September 2001 (see
Appendix A). The questionnaire was developed in con-
junction with the Health service research unit and
department of general practice in the University of
Aberdeen. The general practitioners were asked
about whether they would treat risk factors in patients
with intermittent claudication. Further specific ques-
tions were asked about the following risk factors: anti-
platelet therapy, exercise, diabetes, cholesterol and
smoking. The questionnaire was anonymous and no
reminders were sent out.
Patient survey
One hundred and four consecutive patients present-
ing with claudication to the Grampian Vascular Out-
Patients clinic at Aberdeen Royal Infirmary were
asked to complete a questionnaire regarding risk fac-
tor management. All patients surveyed were referred
by GPs before the GP questionnaires were sent out.
Questionnaires were completed by the patient before
they were seen by a doctor and only those from
patients in whom the diagnosis of intermittent clau-
dication was correct were analyzed. A further 21
patients were referred by the GP with a diagnosis of
intermittent claudication which was not confirmed on
clinical grounds and have, therefore, not been
included in this analysis. The patients were referred
by 100 of the GPs included in the postal survey.
Patients were asked about whether they had under-
gone any blood investigations, what treatment they
were on and what advice they had been given by
their general practitioner. The responses of the
patients were cross-checked with the information pro-
vided by the GP in the referral letter. Blood glucose,
HbA1c, and serum cholesterol levels were measured at
the clinic. Ethical approval was sought but was
deemed unnecessary by local ethical committee.Results
A 73% response rate was received from the GP postal
questionnaire. The first question asked GPs how they
would manage patients with intermittent claudication
at initial presentation (Fig. 1). The vast majority of GPs
recognized the importance of risk factor management
with 50% stating that they would undergo a period of
risk factor management and reassess prior to referral,
and 45% would treat risk factors and refer directly to
the vascular OP clinic. The management of individual
risk factors will be discussed below and compared to
the findings in clinic patients. No significant differ-
ences in risk factor management were noted between
male and female patients attending the clinic.
Patients
One hundred and four consecutive new patients with
intermittent claudication completed the patient ques-
tionnaire. There were 57 males and 47 females (F:M
ratio 1:1.2), with a median age of 70 years (range 41±
85) (Table 1). The mean (standard deviation) estimatedEur J Vasc Endovasc Surg Vol 26, September 2003
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mean (standard deviation) ankle-brachial pressure
index was 0.67 (0.19). The patients had significant
cardiac co-morbidity with 32% having a history of
angina or myocardial infarction, 12% had coronary
artery by-pass grafting and 43% were on anti-hyper-
tensive therapy.
Risk factors
Aspirin
Ninety percent of the GPs stated that they would
prescribe aspirin routinely to patients with intermit-
tent claudication and 71% would prescribe clopido-
grel if the patient had a contra-indication to aspirin.
Amongst the patients surveyed 59% were prescribed
aspirin and 7% self-medicated. One percent was tak-
ing clopidogrel and 5% were on warfarin. In total 72%
of the 104 patients with claudication were on anti-
platelet or anti-coagulant medication. Of the remain-
ing patients, 8% complained of side effects to aspirin
and thus 20% were not an aspirin and had no contra-
indication to the drug.
Physical exercise
Eighty-nine percent of GPs stated that they advise
claudicants to increase their level of activity. Only 15
(14%) patients could recall being given advice to
increase their level of physical activity. Only five
(5%) of the GP letters had any reference to advice
about exercise.
Diabetes and HbA1c measurement
When asked if they would measure blood glucose
levels, 77% of GPs stated that this was their normal
practice. Only 29% of the 104 patients attending the
clinic could recall having their blood glucose checked
and another 30% were unsure. Only in 12 of these
patients did the GP referral letter mention the
patient's blood glucose level. There were 16% known
diabetics and of the remaining 86 patients 12 (14%)
were found to have a HbA1c level greater than 6.5
which is indicative of diabetes.9
Cholesterol measurement and treatment
Eighty-five percent of GPs would routinely check
serum cholesterol levels in patients with claudication.
Only 53 (51%) of the patients could recall having their
serum cholesterol checked and 26 (25%) were unsure.
The levels of cholesterol that GPs would treat are
shown in Table 1. It is of note that 18% of GPs stated
that they would not treat cholesterol in claudicants
unless other risk factors were present. First lineEur J Vasc Endovasc Surg Vol 26, September 2003management consisted of dietary advice in 70% and
statin and diet in 30%. Eighteen percent of GPs stated
that they exercised an age limit to commencing lipid-
lowering therapy. The age limits were as follows: 70
years, n 4 (2%); 75 years, n 20 (8%); 80 years, n 17
(7%) and two (1%) would not treat patients over 85
years of age. Eighty-five percent of patient were on a
statin or had a cholesterol above 5 mmol/l. Thirty-
nine patients were on a statin, of these 18 (46%) still
had a cholesterol level over 5 mmol/l and eight (21%)
had a cholesterol level above 5.5 mmol/l. Of the 65
patients not on a statin the cholesterol levels were
as follows: 55 mmol/l, n 16; 5±5.4 mmol/l, n 7;
5.5±5.9 mmol/l, n 14; and46 mmol/l n 28.
Cigarette smoking
Nearly all (99%) of GPs stated that they would advise
patients to stop smoking and had access to a smoking
cessation clinic. Eighty-seven percent would prescribe
nicotine replacement therapy. Thirty-nine percent of
patients admitted to smoking, and 44% claimed to
have stopped smoking, 15% within the previous
year. Seventeen percent had never smoked. In the GP
referral letter, there was no mention of the smoking
status in 32 cases (31%). Only 34 (85%) of the smokers
could recall being advised to stop smoking and 31
(78%) had been given an explanation of the effects of
smoking on their condition. Only seven (18%) of the
39 smokers had been given any further help to stop
smoking.
Discussion
It is generally accepted that the first line management
of patients with intermittent claudication is `` best
medical therapy'' aimed at reducing risk factors and
advice to exercise regularly. Housley, in a 1988 leading
article summarized the treatment of claudication
as `` Stop smoking and keep walking''.10 In 1988, the
Scottish Intercollegiate guideline network recom-
mended that in addition all claudicants should be
prescribed aspirin. Also in 1998, the Joint British
recommendations on prevention of coronary heart
disease in clinical practice stated that patients with
peripheral vascular disease were `` just as likely to die
from a heart attack as many patients who have
survived there first myocardial infarction'' and recom-
mended that they should be managed in the same way
as those with established coronary heart disease.6 This
includes the detection and treatment of diabetes and
lipid abnormalities.
In this survey we have revealed deficiencies in
the management of each of the following risk
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terol, and smoking. Firstly with regards to anti-plate-
let therapy, although the majority of the GPs
questioned stated that they would prescribe aspirin
to claudicants this does not appear to occur in practice
as over a quarter of the patients surveyed were on
no anti-platelet or anti-coagulant medication. Anti-
platelet therapy protects against non-fatal myocardial
infarction, non-fatal stroke and vascular death in
patients with intermittent claudication.11 It is surpris-
ing that despite the unequivocal evidence for the use
of aspirin and the presence of national guidelines that
it is still not standard practice for all claudicants to be
prescribed an antiplatelet agent.
Exercise has been clearly shown to be of benefit, not
only in terms of secondary prevention but also in its
ability to increase patients' walking distance in struc-
tured programmes.12 Most GPs in this survey stated
that they would advise claudicants to increase their
level of physical activity but only a small minority of
patients (14%) could recall being advised to do so.
Patient recall may be inaccurate, but clearly there is a
huge discrepancy here on what is one of the most
fundamental and basic treatment options available.
Diabetes has long been recognised as a major
risk factor for peripheral vascular disease. In the
Framingham Trial, the age-adjusted risk ratio for
intermittent claudication in diabetic patients com-
pared to controls was five times greater for men and
four times greater for women.13 All patients with
intermittent claudication should have blood glucose
measured in order to identify patients with diabetes.
Surprisingly only 77% of the GPs questioned stated
that they would measure blood glucose in this group
of patients. Furthermore, 12 of the 104 patients were
found to be previously undiagnosed diabetics.
To date, there have been three published major ran-
domised controlled secondary prevention trials invol-
ving statins ± the Scandinavian simvastatin survival
study (4S),14 the cholesterol and recurrent events trial
(CARE)15 and the long term intervention with pravas-
tatin in ischaemic disease study (LIPID).16 These have
totaled over 17 000 patients and have shown that total
mortality and major coronary events can be signifi-
cantly reduced by lowering cholesterol with statin
therapy in patients with a history of cardiac disease.
Until recently the effect of lipid reduction in
patients with isolated peripheral vascular disease has
not been studied. However, the Joint British Recom-
mendations on prevention of coronary heart disease5
has stated that what evidence there is available sup-
ports the treatment of claudicants with statins with the
aim of reducing the serum cholesterol to less than
5 mmol/l. In our study, 1 in 7 of the GPs questionedwould not even check serum cholesterol level in
claudicants. Furthermore, 18% of GPs consider choles-
terol lowering therapy to be primary rather than sec-
ondary prevention and thus would not start statin
therapy in claudicants irrespective of the cholesterol
level unless they had other risk factors. Furthermore,
despite the recommendations to reduce cholesterol
levels to less than 5 mmol/l, 41% of GPs in our survey
would only treat levels above 5.5 mmol/l. Of the 65
patients not on statin therapy, 49 (75%) had a choles-
terol level greater than 5 mmol/l and 42 (65%) of these
had a level greater than 5.5 mmol/l. Nearly half the
patients on a statin had a cholesterol greater than
5 mmol/l suggesting suboptimal therapy. In total,
85% of patient were on a statin or had a cholesterol
above 5 mmol/l, illustrating how common lipid abnor-
malities are in claudicants.
Recently the Heart Protection Study17 has shown
that treatment with simvastatin 40 mg results in a
40% reduction in total mortality, vascular mortality,
coronary heart disease events, strokes and non-
coronary revascularisations in patients with peri-
pheral vascular disease. The Heart Protection Study
has shown that statin therapy should be provided to
all patients with intermittent claudication providing
their cholesterol is greater than 3.5 mmol/l. This
represents a considerable change in current practice,
which may be difficult to achieve given that our
current guidelines are not being met.
Smoking cessation reduces the risk of mortality in
patients with coronary heart disease and benefits are
observed within one year of stopping smoking.18
Encouraging patients to stop smoking, reinforced at
several visits has been shown to double the smoking
cessation rate.19 Similarly nicotine replacement ther-
apy increases quit rate by approximately two-fold.20
Antidepressants (bupropion and nortriptyline) have
also been found useful in helping patients to stop
smoking.21 Practically all the GPs in our study stated
that they would advise their patients to stop smoking
and a significant proportion (485%) would prescribe
nicotine replacement therapy. However only a small
proportion (10%) of smokers in our patient group had
been prescribed nicotine replacement therapy. Thus
with regards to smoking claudicants again appear to
be receiving suboptimal therapy.
In this study we have shown that risk factors are
common in claudicants and are clearly being managed
suboptimally. While general practitioners claim that
they would treat risk factors in claudicants, a signifi-
cant proportion would not test for major risk factors
and would not treat risk factors optimally. This may
in part be due to the paucity of guidelines for the
management of specific risk factors in patients withEur J Vasc Endovasc Surg Vol 26, September 2003
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Clearly, the basic message even with regards to aspirin
and exercise is not being conveyed into clinical
practice. Furthermore this is not a problem unique to
this area as other health regions have highlighted
deficiencies in risk factor management in vascular
patients.22 It may be that GPs wish the diagnosis of
IC to be confirmed prior to initiating treatment of risk
factors. Indeed in this patient survey almost one fifth
of patients referred with a diagnosis of intermittent
claudication by the GPs were not found to have
peripheral vascular disease. However, 50% of GPs
stated that they would undergo a period of risk factor
management and reassess prior to referral and 45%
would treat risk factors and refer directly. We of
course are unable to comment on the practices of the
27% of GPs who did not respond to the questionnaire.
It does, however provide a unique insight into GPs'
attitudes and management of patients with intermit-
tent claudication. What is unclear is how well vascular
surgeons manage these risk factors or whether they
assume that they are being investigated and treated in
primary care. We are currently performing a survey of
the members of the vascular surgeons of Great Britain
and Ireland to evaluate this.
In conclusion, risk factors in claudicants are being
suboptimally investigated and treated in the commu-
nity. Urgent guidelines for general; practitioners on
the specific management of patients with intermittent
claudication, as well as strategies to ensure their imple-
mentation, are required.
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